Drugs in Treatment of Developmental Dyslexia
Abstract
An acute 2 day trial of methylphenidate (10 mg) and of meclizine (12.5 mg) and a 6 month crossover placebo-controlled chronic trial of meclizine (12.5 mg) in children with developmental dyslexia are reported from the University of Calgary, Alberta, Canada.
DOI: https://doi.org/10.15844/pedneurbriefs-2-12-12 | Journal eISSN: 2166-6482
Language: English
Page range: 96 - 96
Published on: Dec 1, 1988
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services
Keywords:
© 1988 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.